Atea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
AVIR•Key figures and analyst view
| Metric | Actual |
|---|---|
| Q2 loss per share | $0.41 |
The current average analyst rating on the shares is buy, with 2 strong buy or buy ratings, 1 hold rating and no sell or strong sell ratings.
The median 12-month price target for Atea Pharmaceuticals is $8.00, about 58.4% above its August 11 closing price of $5.05.
Pipeline and regulatory outlook
Atea expects topline results from its C-FORWARD Phase 3 trial in early Q1 2027.
The company plans to submit an NDA for BEM/RZR to the U.S. FDA in Q2 2027.
Atea is also advancing a Phase 1 trial of AT-587 for HEV in immunocompromised patients.
Q2 loss narrows as expenses decline
Atea Pharmaceuticals reported that its second-quarter net loss per share narrowed from the prior year, as research and development and administrative expenses declined.
Related News
Scilex Holding Co Enters Promissory Note With Vivasor For Revolving Credit Up To $20 Million, On Aug 8
SCLX•
NetApp EVP, Chief Administrative Officer Elizabeth M. O’Callahan sells 1,000 common shares for $193,820
NTAP•
